Protara Therapeutics Inc (OQ:TARA)

May 02, 2024 08:00 am ET
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the first quarter ended March 31, 2024 and provided a...
Apr 05, 2024 08:04 am ET
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has entered into a subscription agreement for the sale of an aggregate of...
Apr 05, 2024 08:02 am ET
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on...
Apr 05, 2024 08:00 am ET
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive data from three-month evaluable carcinoma in situ (CIS) patients treated...
Mar 13, 2024 08:00 am ET
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the full year and fourth quarter ended December 31, 2023...
Feb 28, 2024 08:00 am ET
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual...
Jan 31, 2024 07:30 am ET
Protara Therapeutics to Participate in Upcoming Investor Conferences
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:...
Nov 30, 2023 08:30 am ET
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced additional encouraging data from the Phase 1a dose-escalation component of its...
Nov 03, 2023 08:00 am ET
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a...
Oct 23, 2023 08:00 am ET
Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that dosing is now underway in the Phase 2 STARBORN-1 trial evaluating TARA-002,...
Sep 20, 2023 08:30 am ET
Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that dosing is now underway in its Phase 1b/2 ADVANCED-2 trial evaluating...
Sep 05, 2023 07:30 am ET
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment...
Aug 03, 2023 08:00 am ET
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the second quarter ended June 30, 2023 and provided a...
May 15, 2023 08:00 am ET
Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that patient dosing is now underway in its Phase 1b ADVANCED-1EXP expansion trial...
May 04, 2023 08:00 am ET
Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the first quarter ended March 31, 2023 and provided a...
May 02, 2023 08:00 am ET
Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has received regulatory clearance from the U.S. Food and Drug...
Apr 28, 2023 08:00 am ET
Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive preliminary results from the Phase 1a dose-escalation component of its...
Mar 08, 2023 08:00 am ET
Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the full year and fourth quarter ended December 31, 2022,...
Mar 01, 2023 08:00 am ET
Protara Therapeutics to Participate in Upcoming Investor Conferences
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following upcoming investor conferences:...
Feb 02, 2023 08:00 am ET
Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare...
Jan 30, 2023 08:00 am ET
Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Patrick Fabbio as Chief Financial Officer effective January...
Dec 01, 2022 08:00 am ET
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress poster related to its ADVANCED-1 Phase...
Nov 03, 2022 08:00 am ET
Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the third quarter ended September 30, 2022 and provided a...
Sep 06, 2022 08:00 am ET
Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment...
Aug 09, 2022 08:00 am ET
Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the second quarter ended June 30, 2022 and provided a...
Jun 21, 2022 08:00 am ET
Protara Therapeutics Announces Departure of Chief Financial Officer
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that Blaine Davis, Chief Financial Officer (CFO), has informed the Company that...
May 26, 2022 05:11 pm ET
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress poster related to its ADVANCED-1 Phase...
May 17, 2022 08:00 am ET
Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright Global Investment Conference...
May 12, 2022 08:00 am ET
Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the results of a retrospective analysis of OK-432, the originator compound for...
May 05, 2022 08:00 am ET
Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the first quarter ended March 31, 2022 and provided a...
Mar 24, 2022 08:00 am ET
Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has dosed the first patient in ADVANCED-1, its Phase 1 clinical...
Mar 09, 2022 07:30 am ET
Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the fourth quarter and year ended December 31, 2021 and...
Mar 02, 2022 08:00 am ET
Protara Therapeutics to Participate in Upcoming Investor Conferences
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in fireside chats at two upcoming virtual...
Feb 01, 2022 08:00 am ET
Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the Guggenheim...
Jan 10, 2022 08:00 am ET
Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is...
Jan 04, 2022 08:00 am ET
Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright...
Nov 04, 2021 08:00 am ET
Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the third quarter ended September 30, 2021 and provided a...
Oct 25, 2021 04:45 pm ET
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grants of inducement non-qualified stock options to purchase an aggregate of...
Oct 12, 2021 09:31 am ET
Thinking about buying stock in Protara Therapeutics, Standard Lithium, Lucid Group, Athenex, or FuelCell Energy?
NEW YORK, Oct. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TARA, SLI, LCID, ATNX, and FCEL.
Oct 12, 2021 07:00 am ET
Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared the Company’s...
Sep 17, 2021 04:05 pm ET
Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Oppenheimer Fall...
Sep 13, 2021 07:00 am ET
Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the completion of a retrospective prevalence study...
Sep 07, 2021 08:00 am ET
Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright...
Aug 05, 2021 08:00 am ET
Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the second quarter ended June...
Jul 07, 2021 08:00 am ET
Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Ladenburg...
Jun 10, 2021 08:00 am ET
Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Jane Huang, M.D. to its Board of...
May 13, 2021 08:00 am ET
Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual...
May 06, 2021 07:30 am ET
Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the first quarter ended March...
Apr 23, 2021 07:00 am ET
Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment...
Apr 19, 2021 04:09 pm ET
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options...
Apr 19, 2021 08:00 am ET
Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Martín Sebastian Olivo, M.D. as...
Mar 11, 2021 07:30 am ET
Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the fourth quarter and year...
Mar 10, 2021 08:00 am ET
Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that members of the management team will participate...
Feb 04, 2021 08:00 am ET
Protara Therapeutics to Present at Upcoming Virtual Investor Conferences
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual...
Feb 02, 2021 08:00 am ET
Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Cynthia Smith to its Board of...
Feb 02, 2021 08:00 am ET
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options...
Dec 07, 2020 04:30 pm ET
Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the promotion of Jacqueline (Jackie) Zummo, Ph.D.,...
Dec 03, 2020 07:00 am ET
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options...
Nov 24, 2020 07:00 am ET
Protara Therapeutics to Present at Upcoming Virtual Investor Conferences
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual...
Nov 12, 2020 07:15 am ET
Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the third quarter...
Nov 11, 2020 07:00 am ET
Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that its Chief Executive Officer, Jesse Shefferman,...
Nov 04, 2020 07:00 am ET
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options...
Sep 22, 2020 08:12 am ET
Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the pricing of two concurrent but separate...
Sep 21, 2020 04:01 pm ET
Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that it intends to offer and sell shares of its...
Sep 08, 2020 07:00 am ET
Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced its development plans for TARA-002 in both...
Sep 02, 2020 05:49 pm ET
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, today announced the grants of inducement non-qualified stock...
Aug 03, 2020 07:00 am ET
Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview
Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second quarter ended June 30, 2020. “We are...
Jul 28, 2020 07:00 am ET
Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric...
Jul 24, 2020 07:00 am ET
Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced the appointment of Barry P. Flannelly, Pharm.D, to its Board of Directors. Dr....
Jul 02, 2020 04:05 pm ET
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, today announced the grants of inducement non-qualified stock...
Jun 02, 2020 04:05 pm ET
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, today announced the grants of inducement non-qualified stock...
May 26, 2020 08:30 am ET
Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
May 13, 2020 08:00 am ET
Protara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the first quarter ended March 31, 2020. “We remain keenly...
May 11, 2020 08:38 am ET
ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics
ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its name to Protara Therapeutics, Inc., effective...
May 05, 2020 04:05 pm ET
ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ArTara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, today announced the grants of inducement non-qualified stock...
Apr 02, 2020 07:00 am ET
ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ArTara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, today announced the grants of inducement non-qualified stock...
Feb 11, 2020 08:00 am ET
ArTara Therapeutics Appoints Blaine Davis as Chief Financial Officer
ArTara Therapeutics, Inc. (Nasdaq: TARA) (“ArTara” or the “Company”), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, today announced the appointment of Mr....
Jan 09, 2020 01:43 pm ET
ArTara Therapeutics Completes Merger Transaction with Proteon Therapeutics
ArTara Therapeutics, Inc. (Nasdaq: TARA) (“ArTara” or the “Company”), a clinical-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced the completion of the merger with Proteon...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.